Sorrento Therapeutics
Présence
Sorrento Therapeutics est une société cotée sous le symbole boursier SRNE (US).
Dirigeants
Voir l'organigramme avec ses 25 principaux dirigeants
Biographies les plus recherchées chez Sorrento Therapeutics
Créer une alerte
pour suivre les mouvements de dirigeants chez Sorrento Therapeutics.
Pharmacie
Sorrento Therapeutics a 1 861 concurrents dont Pfizer (Etats—Unis), Sanofi (France) et Johnson & Johnson (Etats—Unis).
Actualités en fusion/acquisition en Pharmacie.
- MedMen has filed for bankruptcy protection (publié le 28 avril 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (publié le 23 mars 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (publié le 19 mars 2024).
Contacts en Pharmacie
Actualités
Derniers communiqués de presse par Sorrento Therapeutics
- Sorrento Completes Successfully the SAD Study and Initiates the MAD Phase 1 Study with STI-1558, An Oral M(pro) Inhibitor as a Standalone Treatment and Prevention of COVID-19 without the Ritonavir as Booster | Sorrento Therapeutics
- Sorrento Therapeutics Announces the FDA IND Clearance of STI-1558, An Oral M(pro) and Cathepsin L Inhibitor to Treat COVID-19 | Sorrento Therapeutics
- Scilex Holding Company, a Sorrento Company, Has Entered A Term Sheet to Acquire Ancora Medical Inc. | Sorrento Therapeutics
- News Releases | Sorrento Therapeutics
- Scilex Holding Company, a Sorrento Company, announces that the Honorable Tommy G. Thompson has joined the Scilex Board of Directors | Sorrento Therapeutics
- Sorrento Therapeutics, Inc. announces the appointment of the Honorable Tommy G. Thompson, as Covid-19 Special Consultant to Chairman and CEO Henry Ji | Sorrento Therapeutics
- Scilex Holding Company, a Sorrento Company, enters into an agreement for an exclusive license with ROMEG Therapeutics, LLC, for the right to commercialize Gloperba®, an FDA-approved prophylactic treatment for painful gout flares in adults, in the US. | So
- Scilex Holding Company, a Sorrento Company, Announces Pre-Emptive Repurchase of $41.4 Million of its Senior Secured Notes | Sorrento Therapeutics
- Sorrento Therapeutics Announces First Subject Dosed in a Phase I Clinical Study of STI-1558, an Oral Mpro Inhibitor as a Standalone Treatment and Prevention of COVID-19 Without Co-Administration of Ritonavir Booster | Sorrento Therapeutics
- Scilex Holding Company, a Sorrento Company, announces continued growth in ZTlido® in managed health care plans | Sorrento Therapeutics
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de Sorrento Therapeutics
- Sorrento Therapeutics sur Wikipédia, Google News & Yahoo Finance en 1-click
- Sorrento Therapeutics sur LinkedIn, Twitter & YouTube en 1-click
Entrer en contact
Contacter par email ses dirigeants dont Henry Ji 
Appelez Sorrento Therapeutics au +1 858...
